LimmaTech pays for rights to AbVacc's vaccine candidate

20 December 2023

Privately-held Swiss firm LimmaTech Biologics has announced a license agreement that grants the company exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02).

This vaccine is designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus).

LimmaTech is convinced that the vaccine has the potential to solve the challenges posed by targeting S. aureus surface antigens by addressing a new mechanism of action that has not been explored before.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK